The best RI-3 antagonist, which as expected was stable to incubation in serum, inhibited, at nanomolar concentration, migration, matrigel invasion and trans-endothelial migration of human sarcoma cells, and blocked VEGF-triggered endothelial tube formation. Here, VEGFA is linked to sarcoma.